Policies should align with patients’ and providers’ growing support of biosimilars, but the therapies’ adoption has been slowed by patent litigation and price manipulation, industry observers said.
Policies should align with patients’ and providers’ growing support of biosimilars, but the therapies’ adoption has been slowed by patent litigation and price manipulation, industry observers said.